A Phase II Study of TAK-228 in patients with previously treated metastatic renal cell carcinoma
|Effective start/end date
|9/1/17 → 9/30/22
- DANA-FARBER CANCER INSTITUTE
- MILLENNIUM PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.